Topics: | Anemia of CKD | SGLT2 Inhibitors & CKD | Executive Order on Advancing Kidney Health

Role of the SGLT2 Inhibitors in Patients with T2DM, CKD, and CVD

 

Overview

Diabetic renal disease and cardiovascular disease (CVD) persist as widespread conditions associated with substantial costs and morbidity in the United States. More than 35% of people 20 years or older with diabetes have chronic kidney disease (CKD). Recent estimates reveal that total Medicare spending on both CKD and end-stage renal disease was over $114 billion. Nearly 800,000 Americans die each year from CVD and about one in every six US healthcare dollars is spent on CVD.

Fortunately, recently published data have revealed that the sodium-glucose cotransporter-2 (SGLT2) inhibitors have the potential to prevent CKD progression and improve cardiovascular outcomes in patients with type II diabetes mellitus (T2DM) and CKD. This CME activity, Role of SGLT2 Inhibitors in Patients with T2DM, CKD, and CVD, will help participants better understand and apply the renal and CV outcomes data when using SGLT2 inhibitors.

Agenda

I. Welcome and Introduction
II. Staying Current with the Latest SGLT2 Inhibitor Trial Data in T2DM, CVD, and CKD
III. Applying the Current SGLT2 Inhibitor Renal and CV Outcomes Data into Optimal Treatment Regimens
IV. Q&A Session and Concluding Remarks

Learning Objectives

This program is designed to address the following National Academy of Medicine (NAM) competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to:

• Evaluate the safety and efficacy data of the SGLT2 inhibitors in patients with type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and cardiovascular disease (CVD)
• Incorporate available SGLT2 inhibitors into appropriate and effective T2DM, and CKD, and CVD treatment plans

Target Audience

This activity is intended for nephrologists and nurse practitioners who manage patients with type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and cardiovascular disease (CVD).

Physician Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Physician Designation Statement

The Potomac Center for Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email contact@potomacme.org.

ABIM MOC Designation Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

MIPS Credit Designation Statement

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

In order to fulfill requirements for MIPS improvement activity, participants will need to fill out 2 brief follow-up surveys at 30- and 90-days post-activity.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Rockpointe Corporation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Steering Committee

Rajiv Agarwal, MD, MS
Professor of Medicine
Indiana University
Indianapolis, IN

Matthew R. Weir, MD
Professor of Medicine
Chief, Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, MD

Disclosure Statement

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

Disclosures will be made known to participants prior to the activity.

Jointly provided By

Provided By

Educational Partner

Supporters

This activity is not supported by any commercial interest or grantor.